Puma Biotechnology Reports 11% Revenue Growth, Returns to Profitability Q2 2025

Puma Biotechnology reported strong second-quarter 2025 results, marking a return to profitability with GAAP net income of $5.9 million and non-GAAP EPS of $0.15, surpassing analyst estimates. The company saw an 11.2% increase in GAAP revenue to $52.4 million, driven primarily by growth in sales of its core product, NERLYNX, an oral drug targeting HER2-positive breast cancer. Operating expenses decreased due to lower selling, general, and administrative costs, while R&D expenses rose slightly amid ongoing clinical trials for alisertib, an investigational cancer treatment. Puma reiterated its full-year guidance, projecting GAAP revenue between $212 million and $222 million and net income between $23 million and $28 million, supported by strong demand for NERLYNX and pipeline advancements. The company also anticipates key clinical data presentations in the near future, reinforcing optimism about its financial outlook. Despite recent stock performance slightly lagging the broader market, ongoing earnings beat trends and positive revisions underpin a favorable investment sentiment.